Literature DB >> 3230720

Clinical studies of Vogt-Koyanagi-Harada's disease.

S Ohno1, R Minakawa, H Matsuda.   

Abstract

We evaluated the clinical statistics of a total of 186 patients (101 men and 85 women) with Vogt-Koyanagi-Harada's disease seen in the Uveitis Survey Clinic of the Hokkaido University Hospital during the 18-year period from 1966 to 1983. The annual number of new cases showed some change. More new patients were seen in the spring and late autumn. Clinical examination at the first visit concerning ocular symptoms showed inflammatory cells in the anterior chamber in 56%, papilledema in 87%, and serous retinal detachment and/or retinal edema in 93% of the cases. During the course of the disease, 64% of the cases showed depigmentation of the ocular fundus, and 85% showed perilimbal vitiligo (Sugiura's sign). In addition, the clinical examinations concerning extraocular symptoms showed pleocytosis in the cerebrospinal fluid in 84%, dysacousia in 74%, and scalp supersensitivity on touching the hair in 72% of the cases. Visual prognosis was generally favorable, but the final visual acuity in this disease was significantly affected by ocular complications, initial visual acuity, and the age at onset.

Entities:  

Mesh:

Year:  1988        PMID: 3230720

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  20 in total

1.  Anterior ischemic optic neuropathy associated with Vogt-Koyanagi-Harada disease.

Authors:  Kumiko Nakao; Yuka Mizushima; Noriko Abematsu; Nanako Goh; Taiji Sakamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-30       Impact factor: 3.117

2.  Visual function in Vogt-Koyanagi-Harada patients.

Authors:  Soon-Phaik Chee; Chi D Luu; Ching-Li Cheng; Wee-Kiak Lim; Aliza Jap
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-11       Impact factor: 3.117

3.  Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.

Authors:  S Otani; T Sakurai; K Yamamoto; T Fujita; Y Matsuzaki; Y Goto; Y Ando; S Suzuki; M Usui; M Takeuchi; Y Kawakami
Journal:  Br J Ophthalmol       Date:  2006-02-15       Impact factor: 4.638

4.  Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.

Authors:  Sabine Aisenbrey; Christoph Lüke; Helen D Ayertey; Salvatore Grisanti; Andreas Perniok; Richard Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

5.  Characterization of serous retinal detachments in uveitis patients with optical coherence tomography.

Authors:  Annamieka Simmons-Rear; Steven Yeh; Brian T Chan-Kai; Andreas K Lauer; Christina J Flaxel; Justine R Smith; James T Rosenbaum; Eric B Suhler
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-06-02

6.  Prognostic factors in Vogt-Koyanagi-Harada disease.

Authors:  Abdullah S Al-Kharashi; Hassan Aldibhi; Hamad Al-Fraykh; Dustan Kangave; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2007-04-14       Impact factor: 2.029

7.  Vogt-Koyanagi-Harada disease in elderly Japanese patients.

Authors:  Chihiro Kiyomoto; Masamoto Imaizumi; Kenichi Kimoto; Hiromi Abe; Satoko Nakano; Kazuo Nakatsuka
Journal:  Int Ophthalmol       Date:  2007-04-14       Impact factor: 2.029

8.  The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.

Authors:  Moncef Khairallah; Sonia Zaouali; Riadh Messaoud; Sami Chaabane; Sonia Attia; Salim Ben Yahia; Kamel Hmidi
Journal:  Int Ophthalmol       Date:  2007-01-04       Impact factor: 2.029

9.  Reversible alopecia in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia.

Authors:  Chiu-Tung Chuang; Po-Sian Huang; Shih-Chou Chen; Shwu-Jiuan Sheu
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-15

10.  Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease.

Authors:  Masaru Miyanaga; Tatushi Kawaguchi; Kentaro Shimizu; Kazunori Miyata; Manabu Mochizuki
Journal:  Int Ophthalmol       Date:  2007-05-03       Impact factor: 2.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.